5439602025-10-012025-12-315439602025-04-012025-12-315439602025-10-012025-12-31in-capmkt:OtherExpenses1Member5439602025-10-012025-12-31in-capmkt:OtherExpenses2Member5439602025-04-012025-12-31in-capmkt:OtherExpenses1Member5439602025-04-012025-12-31in-capmkt:OtherExpenses2Member5439602025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15439602025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25439602025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35439602025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss45439602025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15439602025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25439602025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35439602025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss45439602025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15439602025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15439602025-10-012025-12-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares543960CONCORDBIONAINE338H01029Concord Biotech LimitedMain BoardEquity2025-04-012026-03-312026-02-112026-02-06INRLakhsQuarterlyThird quarterSingle segmentPharmaceuticals2026-02-1117:00:002026-02-1118:22:00Declaration of unmodified opinion2025-10-012025-12-31UnauditedConsolidated2777660000997620002877422000665928000204447000-2130270004678070008150001874690006627010001976140000901282000-3275400086852800021568300094610002251440000643384000000-6969000636415000229473000865888000644766000-8351000874563000-867500010461600016.086.08006.086.081.The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on 11th february, 2026. The Statutory Auditors of the company have carried out a limited review of the said results. <BR> 2.The unaudited consolidated financial results of the Group include information of wholly owned subsidiary Concord Lifegen Limited (w.e.f 21st July 2025), subsidiary Stellon Biotech Inc. (w.e.f 1st July 2025) and joint venture Concord Biotech Japan K.K. <BR> 3.The Group is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - "Operating Segment". <BR> 4. On 21 November 2025, the Government of India notified four labour codes consolidating 29 existing labour laws. The Ministry of Labour and employment has issued draft central rules and FAQs to facilitate assesment of financial impact arising from these changes. Based on management's assessment including valuation, considering the best information available and ICAI guidance, the Company has recognised an incremental Liability of Rs. 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under new labour codes. Considering the event as regulatory driven and non recurring nature, the impact of the same has been disclosed under exceptional items in the standalone results for the quarter and nine months ended 31 December 2025. The Company continues to monitor the notification of final Central/State rules and related clarifications and will evaluate and account for any additional impact in the period in which such rules are notified or clarifications issued. <BR> 5. The above consolidated financial results has been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 read together with Companies (Indian Accounting Standards) Rules, 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI").2025-04-012025-12-31UnauditedConsolidated728811100037005900076581700001838069000469361000-70886800012913360001992000549147000190952900053505660002307604000-327540002274850000576428000216680005980960000167675400000030868000170762200041980200021274240001721154000-135320002141417000-13993000104616000116.3216.320016.3216.32Power and Fuel284366000Other Expenses378335000Power and Fuel864396000Other Expenses1045133000Re-measurement gain/ (loss) on defined benefit plans-6344000Income tax relating to re-measurement gain/ (loss) on defined benefit plans1597000Fair value changes on equity investments through OCI274813000Income tax relating to fair value changes on equity investments through OCI-39298000230768000Re-measurement gain/ (loss) on defined benefit plans-9350000Income tax relating to re-measurement gain/ (loss) on defined benefit plans2353000Fair value changes on equity investments through OCI500167000Income tax relating to fair value changes on equity investments through OCI-7152400042164600000Foreign currency translation reserves-1295000-1295000Foreign currency translation reserves-1844000-184400000229473000419802000UnauditedtrueB S R & Co. LLPtrue2028-07-31